Bouadjar B, Aït-Belkacem F, Daya-Grosjean L, Sarasin A, Larbaoui S L, Ferhat R, Cherid M C, Bendissari A, Chouiter A, Bouzid K, Henni T, Hafiz A, Allouache A, Ysmail-Dahlouk M
Clinique de Dermatologie, CHU Mustapha, Alger.
Ann Dermatol Venereol. 1996;123(5):303-6.
Xeroderma pigmentosum (XP) is a rate autosomal recessive disorder related to DNA repair defects. Recently, modifications of oncogenes and mutations of the p53 suppressor gene have been reported in skin tumors of XP patients. The purpose is to study, through a series of 40 patients admitted to the Dermatologic Clinic of Algiers, the characteristics of XP in Algeria.
For each patient, familiarity, clinical and biological examinations and therapeutic results were studied. Biological studies have been axed mainly on analysis of DNA extracted from skin tumors of 18 patients to detect oncogene modifications by Southern blot and hybridization. A technic, based on single strand DNA conformation polymorphism (SSCP), has been carried out to detect rapidly mutations on the p53 gene.
A consanguinity in the first degree is noted in 95 p. 100 of cases and a familiarity in 63 p. 100 of cases. The median age of patients is 10 years; sex ratio is close to one; 32 patients (80 p. 100) are classic XP and 8 (20 p. 100) are XP variant. In 18 tumors analysed, the Ha-ras gene is amplified and/or modified in 50 p. 100 of cases. Only 3 tumors (16.6 p. 100) show mutations of the p53 gene (transitions C-T). Surgical treatment isolated or associated to polychemotherapy permitted to resolve tumors in 75 p. 100 of cases.
In Algeria, XP are mainly classic with a particularly high frequency of occular (62 p. 100) and neurological manifestations (62 p. 100). Genetic studies confirm modifications of the Haras gene in direct relation with unrepaired UV lesions in classic XP and mutations of the p53 tumor suppressor gene characteristic of mutation spectra induced by UV. Surgery is the treatment of choice for tumors; polychemotherapy is an alternative in advanced cases.
着色性干皮病(XP)是一种与DNA修复缺陷相关的罕见常染色体隐性疾病。最近,在XP患者的皮肤肿瘤中报道了癌基因的改变和p53抑癌基因的突变。目的是通过对阿尔及尔皮肤科诊所收治的40例患者进行一系列研究,了解阿尔及利亚XP的特征。
对每位患者进行家族史、临床和生物学检查以及治疗结果研究。生物学研究主要集中在对18例患者皮肤肿瘤提取的DNA进行分析,通过Southern印迹和杂交检测癌基因改变。采用基于单链DNA构象多态性(SSCP)的技术快速检测p53基因的突变。
95%的病例有一级亲属近亲结婚,63%的病例有家族史。患者的中位年龄为10岁;性别比接近1;32例患者(80%)为典型XP,8例(20%)为XP变异型。在分析的18个肿瘤中,50%的病例中Ha-ras基因被扩增和/或改变。只有3个肿瘤(16.6%)显示p53基因的突变(C-T转换)。手术治疗单独或联合多化疗使75%的病例肿瘤得到解决。
在阿尔及利亚,XP主要为典型类型,眼部表现(62%)和神经学表现(62%)的发生率特别高。遗传学研究证实,典型XP中Haras基因的改变与未修复的紫外线损伤直接相关,以及p53肿瘤抑制基因的突变是紫外线诱导的突变谱特征。手术是肿瘤的首选治疗方法;多化疗是晚期病例的一种选择。